Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan Tamargo

Showing results (1-10 of 184) with videos related to

Pageof 19
Sort By:
European Cardiology|January 15, 2020
Corrigendum to: Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future DevelopmentsJuan Tamargo
European Cardiology|September 18, 2020
Treatment of Coronavirus Disease 2019: Shooting in the DarkJuan Tamargo
European Cardiology|May 28, 2019
Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future DevelopmentsJuan Tamargo
Cardiac Failure Review|August 9, 2017
The Mechanism of Action of LCZ696Juan Tamargo Menendez
Anales De La Real Academia Nacional De Medicina|January 29, 2013
[Differences in atrial remodelling between right and left atria in patients with chronic atrial fibrillation]Juan Tamargo Menéndez
Anales De La Real Academia Nacional De Medicina|December 12, 2007
[New strategies in the treatment of atrial fibrillation]Juan Tamargo Menéndez
European Heart Journal. Cardiovascular Pharmacotherapy|September 11, 2019
Low quality of some generic cardiovascular medicinal products represents a matter for growing concernJuan Tamargo, Giuseppe Rosano
European Heart Journal. Cardiovascular Pharmacotherapy|August 4, 2025
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? . Why can't we see the evidence?Juan Tamargo, Eva Delpón
Expert Opinion on Drug Discovery|May 26, 2017
Future drug discovery in renin-angiotensin-aldosterone system interventionMaria Tamargo, Juan Tamargo
Nephrologie & Therapeutique|June 5, 2017
Renin-angiotensin system blockade: FinerenoneLuis M Ruilope, Juan Tamargo
Pageof 19

Showing results (1-10 of 184) with videos related to

Sort By:
Pageof 19
European Cardiology|January 15, 2020
Corrigendum to: Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future DevelopmentsJuan Tamargo
European Cardiology|September 18, 2020
Treatment of Coronavirus Disease 2019: Shooting in the DarkJuan Tamargo
European Cardiology|May 28, 2019
Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future DevelopmentsJuan Tamargo
Cardiac Failure Review|August 9, 2017
The Mechanism of Action of LCZ696Juan Tamargo Menendez
Anales De La Real Academia Nacional De Medicina|January 29, 2013
[Differences in atrial remodelling between right and left atria in patients with chronic atrial fibrillation]Juan Tamargo Menéndez
Anales De La Real Academia Nacional De Medicina|December 12, 2007
[New strategies in the treatment of atrial fibrillation]Juan Tamargo Menéndez
European Heart Journal. Cardiovascular Pharmacotherapy|September 11, 2019
Low quality of some generic cardiovascular medicinal products represents a matter for growing concernJuan Tamargo, Giuseppe Rosano
European Heart Journal. Cardiovascular Pharmacotherapy|August 4, 2025
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? . Why can't we see the evidence?Juan Tamargo, Eva Delpón
Expert Opinion on Drug Discovery|May 26, 2017
Future drug discovery in renin-angiotensin-aldosterone system interventionMaria Tamargo, Juan Tamargo
Nephrologie & Therapeutique|June 5, 2017
Renin-angiotensin system blockade: FinerenoneLuis M Ruilope, Juan Tamargo
Pageof 19